L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway

Oncology Reports

Volumn 31, Issue 5, 2014, Pages 2245-2251

  Han, Shuwen ^a   Zhang, Gang ^a   Li, Maidong ^a   Chen, Dongyun ^a   Wang, Ying ^b   Ye, Wencai ^b   Ji, Zhaoning ^a  

^a WANNAN MEDICAL COLLEGE   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

Apoptosis; HL 60 cells; L securinine

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SECURININE; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; LACTONE; MTOR PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNTING; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ELECTRON MICROSCOPY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR MECHANICS; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PTEN GENE; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HL 60 CELL LINE; LEUKEMIA, PROMYELOCYTIC, ACUTE; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION; HETEROCYCLIC COMPOUNDS, BRIDGED-RING; HL-60 CELLS; HUMANS; LACTONES; LEUKEMIA, PROMYELOCYTIC, ACUTE; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; S PHASE CELL CYCLE CHECKPOINTS; TOR SERINE-THREONINE KINASES;

EID: 84898612229     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3101     Document Type: Article

References (30)

1. Pui CH: Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 109: 777-787, 2010
2. Kaspers GJ and Creutzig U: Pediatric acute myeloid leukemia: International progress and future directions. Leukemia 19: 2025-2029, 2005
3. Kim KC, Kim JS, Son JK and Kim IG: Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells by the Ganoderma lucidum and Duchesnea chrysantha extracts. Cancer Lett 246: 210-217, 2007
4. Muraveva V and Bankovskii A: Chemical study of alkaloids of Securinega suffruticosa. Doklady Akad Nauk SSSR 110: 998-1000, 1956
5. Saito S, Kotera K, Shigematsu N, Ide A, Sugimoto N, Horii Z, Hanaoka M, Yamawaki Y and Tamura Y: Structure of securinine. Tetrahedron 19: 2085-2099, 1963
6. Imado S, Shiro M and Horii Z: The crystal structure of securinine hydrobromide dihydrate and the molecular structure of securinine. Chem Pharm Bull 13: 643-651, 1965
7. Peng JZ: Securinine pharmacological and clinical progress. J Ningxia Med Coll 16: 2, 1994
8. Beutler JA, Karbon EW, Brubaker AN, Malik R, Curtis DR and Enna SJ: Securinine alkaloids: A new class of GABA receptor antagonist. Brain Res 330: 135-140, 1985
9. CL Y, LQ L and LS S: The treatment of aplastic anemia. Tianjin Med J 9: 662-665, 1981
10. Weenen H, Nkunya MH, Bray DH, Mwasumbi LB, Kinabo LS, Kilimali VA and Wijnberg JB: Antimalarial compounds containing an ?, ?-unsaturated carbonyl moiety from Tanzanian medicinal plants. Planta Med 56: 371-373, 1990
11. Mensah JL, Lagarde I, Ceschin C, Michel G, Gleye J and Fouraste I: Antibacterial activity of the leaves of Phyllanthus discoideus. J Ethnopharmacol 28: 129-133, 1990
12. Chen CR, Xia YH, Yao SY, Zhang Q, Wang Y and Ji ZN: Virosecurinine induces apoptosis by affecting Bcl-2 and Bax expression in human colon cancer SW480 cells. Pharmazie 67: 351-354, 2012
13. Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-198, 2008
14. Burnett PE, Barrow RK, Cohen NA, Snyder SH and Sabatini DM: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95: 1432-1437, 1998
15. West KA, Linnoila IR, Belinsky SA, Harris CC and Dennis PA: Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res 64: 446-451, 2004
16. Janku F, Stewart DJ and Kurzrock R: Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol 7: 401-414, 2010
17. Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 13: 252-266, 2012
18. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004
19. Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S and Berestein GL: Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 5: 95-108, 2007
20. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ and Global AT: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007
21. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D and Oberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523, 2011
22. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D and Hortobagyi GN: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529, 2012
23. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R and Kroemer G: Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 16: 87-93, 2009
24. Huang FF, Wu DS, Zhang L, Yu YH, Yuan XY, Li WJ, Chen XP, Zhao XL, Chen FP and Zeng H: Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett 336: 96-105, 2013
25. Inayat-Hussain SH, Osman AB, Din LB and Taniguchi N: Altholactone, a novel styryl-lactone induces apoptosis via oxidative stress in human HL-60 leukemia cells. Toxicol Lett 131: 153-159, 2002
26. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ and Huang P: Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278: 37832-37839, 2003
27. Li L, Pan S, Zhou X, Meng X, Han X, Ren Y, Yang K and Guan Y: Reduction of in-stent restenosis risk on nickel-free stainless steel by regulating cell apoptosis and cell cycle. PLoS One 8: E62193, 2013
28. Castello-Branco MVS, Tavares JF, Silva MS, Barbosa Filho JM, Anazetti MC, Frungillo L, Haun M, Melo Diniz MF and Melo PS: Xylodiol from Xylopia langsdorfiana induces apoptosis in HL60 cells. Revista Brasileira de Farmacognosia 21: 1035-1042, 2011
29. Nahata A, Saxena A, Suri N, Saxena AK and Dixit VK: Sphaeranthus indicus induces apoptosis through mitochondrial-dependent pathway in HL-60 cells and exerts cytotoxic potential on several human cancer cell lines. Integr Cancer Ther 12: 236-247, 2013
30. Liu S, Wang XJ, Liu Y and Cui YF: PI3K/AKT/mTOR signaling is involved in (-)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells. Am J Chin Med 41: 629-642, 2013